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To the Editor—Lungen and Gerber point to the large
relative reduction in German pharmaceutical research
and development expenditures noted in my editorial
by suggesting that “. . . about 40% of the [pharmaceu-
tical] innovations are mere pseudo-innovations that
are no better for the patient, but simply more expen-
sive for the health insurance.” This is a very strange
criticism. Suppose the only statin ever discovered had
been the innovator lovastatin (Mevacor) under the the-
ory that all other statins are “me-too” and would have
been disallowed. Would the patent holder (Merck)
have been willing to negotiate with governments or
other consumers on price at all? Would the amount of
price competition been anything like what it was with
simvastatin, ﬂuvastatin, pravastatin, atorvatstatin, and
rosuvastatin, also available in the marketplace? It is
precisely the approval of “me-too” drugs that erodes
the pricing power of the original innovator and makes
competition in the pharmaceutical market meaningful.
Far from making things more expensive for health
insurers, this makes things dramatically less expensive.
Moreover, not all pharmaceutical competition has
to take place in price. It was precisely the competitive
jockeying for market share between statin manufactur-
ers Merck, Bristol-Myers Squibb, Pﬁzer, and Novartis
that led to numerous valuable scientiﬁc outcomes trials
as the manufacturers attempted to position their statin
agents as clinically superior to the existing therapies.
This nonprice competition led to major scientiﬁc
advances not only in lipid therapy but also in under-
standing of how arterial plaques cause myocardial inf-
arctions and how the atherosclerotic disease process
works [1].
Finally, the categorization of similar drugs as “inno-
vator” and “me-too” is quite arbitrary. Certainly,
many of the HIV/AIDS reverse transcriptase inhibitor
medications can be classiﬁed as “me-too” after the
innovator AZT, but they have dramatically improved
the available therapeutic options and overcome drug
resistance issues that have impacted AZT’s efﬁcacy [2].
Similarly, cimetadine (Tagamet, GlaxoSmithKline,
Research Triangle Park, NC) was the “innovator” H2
receptor antagonist (H2RA) in the 1970s, but sub-
sequent H2RAs (e.g., ranitadine (Zantac, GlaxoSmith-
Kline)) captured the majority of the H2RA market,
precisely because physicians and patients preferred
these newer drugs on the basis of approved indica-
tions, side effects, drug interactions, or dosing/compli-
ance [3].—Joel Hay, PhD, University of Southern
California, Los Angels, CA.
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